Navigation Links
IDEV Technologies Launches Lower Profile SUPERA VERITAS® Stent Delivery System
Date:7/12/2011

WEBSTER, Texas, July 12, 2011 /PRNewswire/ -- IDEV Technologies, Incorporated (IDEV), today announced the first procedures in Europe utilizing the new 6 French (6Fr) SUPERA VERITAS® Peripheral Vascular System.  The new lower profile delivery system offers physicians more treatment options, easier operation, and greater delivery control, while providing the unique strength, flexibility, and performance benefits of the SUPERA stent.

The 6Fr size allows a smaller access site and multiple approach options when treating patients with peripheral artery disease (PAD), which can be particularly important when treating stenoses or occlusions in the superficial femoral artery (SFA) and the popliteal artery.  In addition to having a lower entry profile, the new 6Fr system is available in two catheter lengths, 80 cm and 120 cm, and offers even better efficiency and trackability.

Initial procedures were done last month at Canisius-Wilhelmina Ziekenhuis (CWZ) in Nijmegen, Netherlands and also at three German sites: Park Hospital in Leipzig, Heart Centre Bad Krozingen, and University Hospital in Heidelberg.  Feedback from the treating physicians has been enthusiastic.

"The new 6Fr system allowed for better control of stent deployment while requiring less force to deliver," commented Andrej Schmidt, MD, PhD, at the Park Hospital.  "In addition, the modified outer sheath easily tracked through tortuous anatomy.  Over the years, IDEV has continued to refine the stent delivery system to provide greater utility and flexibility to physicians."

Dr. Sebastian Sixt of Herz Zentrum (Heart Centre) Bad Krozingen stated, "I appreciate how easily I can control the stent delivery.  The improved delivery makes it very straightforward to predict the stent landing zone, and treat the lesion appropriately."

Dr. Peter Haarbrink of CWZ and Dr. Erwin Blessing at Heidelberg agree the lower profile 6Fr system offers the benefits of the SUPERA stent to portions of the market that were not previously served.  Dr. Haarbrink elaborated, "Many of our procedures utilize 6Fr systems, so having SUPERA VERITAS now available in this size allows us to use our stent of choice without switching to a different sheath."

"Launching the lower profile SUPERA VERITAS system was a key corporate milestone this year," commented Christopher M. Owens, President and CEO of IDEV.  "We are committed to meeting customer needs and working closely with physicians to provide products that are truly differentiated.  This is another example of the Company investing in research and ongoing development to deliver patient benefits."

A full launch of the lower profile 6Fr SUPERA VERITAS Peripheral Vascular System will occur this summer throughout Europe.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.

The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

For more information please visit www.idevmd.com.

Contact:
Donna Lucchesi
Vice President Global Marketing
IDEV Technologies, Incorporated
(281) 525-2000


'/>"/>
SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the ... heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach to solving ... Countless deodorants flood the aisles that contain harmful chemicals that should be put ...
(Date:4/27/2017)... ... , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including ... , The first new location will open at the corner of 27th and Randolph ... Lights Drive this fall. And the third location is in the process of being ...
(Date:4/26/2017)... ... 2017 , ... Jump Technologies, Inc., an innovative software company ... a round of funding to accelerate its growth strategies. The $3.5 million investment ... a growth equity firm focused on investments in healthcare and technology companies. This ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
Breaking Medicine News(10 mins):